ADMA Q2 2019 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+40.9% YoY

Gross Profit

-$4M-59.9% margin

Operating Income

-$11M-172.8% margin

Net Income

-$13M-201.4% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+85.9%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$726,736

Balance Sheet

Total Assets

$143M

Total Liabilities

$96M

Stockholders' Equity

$47M

Cash & Equivalents

$74M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$5M	+40.9%
Gross Profit	-$4M	-$5M	+21.2%
Operating Income	-$11M	-$13M	+15.5%
Net Income	-$13M	-$15M	+10.4%

Revenue Segments

ADMA BioManufacturing

$4M61%

Plasma Collection Centers

$3M38%

Corporate

$35,7091%